Suppr超能文献

新型PARP-1抑制剂AG-690/11026014的合成及其对血管紧张素II诱导的小鼠心脏重塑的保护作用。

Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling.

作者信息

Feng Guo-Shuai, Zhu Cui-Ge, Li Zhuo-Ming, Wang Pan-Xia, Huang Yi, Liu Min, He Ping, Lou Lan-Lan, Chen Shao-Rui, Liu Pei-Qing

机构信息

Department of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.

Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.

出版信息

Acta Pharmacol Sin. 2017 May;38(5):638-650. doi: 10.1038/aps.2016.159. Epub 2017 Feb 27.

Abstract

We previously identified AG-690/11026014 (6014) as a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor that effectively prevented angiotensin II (Ang II)-induced cardiomyocyte hypertrophy. In the present study, we reported a new synthesis route for 6014, and investigated its protective effects on Ang II-induced cardiac remodeling and cardiac dysfunction and the underlying mechanisms in mice. We designed a new synthesis route to obtain a sufficient quantity of 6014 for this in vivo study. C57BL/6J mice were infused with Ang II and treated with 6014 (10, 30, 90 mg·kg·d, ig) for 4 weeks. Then two-dimensional echocardiography was performed to assess the cardiac function and structure. Histological changes of the hearts were examined with HE staining and Masson's trichrome staining. The protein expression was evaluated by Western blot, immunohistochemistry and immunofluorescence assays. The activities of sirtuin-1 (SIRT-1) and the content of NAD+ were detected with the corresponding test kits. Treatment with 6014 dose-dependently improved cardiac function, including LVEF, CO and SV and reversed the changes of cardiac structure in Ang II-infused mice: it significantly ameliorated Ang II-induced cardiac hypertrophy evidenced by attenuating the enlargement of cardiomyocytes, decreased HW/BW and LVW/BW, and decreased expression of hypertrophic markers ANF, BNP and β-MHC; it also prevented Ang II-induced cardiac fibrosis, as implied by the decrease in excess accumulation of extracellular matrix (ECM) components collagen I, collagen III and FN. Further studies revealed that treatment with 6014 did not affect the expression levels of PARP-1, but dose-dependently inhibited the activity of PARP-1 and subsequently restored the activity of SIRT-1 in heart tissues due to the decreased consumption of NAD+ and attenuated Poly-ADP-ribosylation (PARylation) of SIRT-1. In conclusion, the novel PARP-1 inhibitor 6014 effectively protects mice against AngII-induced cardiac remodeling and improves cardiac function. Thus, 6014 might be a potential therapeutic agent for heart diseases..

摘要

我们之前鉴定出AG-690/11026014(6014)是一种新型的聚(ADP-核糖)聚合酶-1(PARP-1)抑制剂,它能有效预防血管紧张素II(Ang II)诱导的心肌细胞肥大。在本研究中,我们报道了6014的一种新合成路线,并研究了其对Ang II诱导的心脏重塑和心脏功能障碍的保护作用以及在小鼠体内的潜在机制。我们设计了一种新的合成路线以获得足够量的6014用于此项体内研究。将C57BL/6J小鼠用Ang II灌注,并给予6014(10、30、90 mg·kg·d,灌胃)处理4周。然后进行二维超声心动图以评估心脏功能和结构。用HE染色和Masson三色染色检查心脏的组织学变化。通过蛋白质印迹、免疫组织化学和免疫荧光分析评估蛋白质表达。用相应的检测试剂盒检测沉默调节蛋白-1(SIRT-1)的活性和NAD+的含量。6014处理剂量依赖性地改善了心脏功能,包括左心室射血分数(LVEF)、心输出量(CO)和每搏输出量(SV),并逆转了Ang II灌注小鼠的心脏结构变化:它显著改善了Ang II诱导的心肌肥大,表现为心肌细胞增大减轻、心脏重量/体重(HW/BW)和左心室重量/体重(LVW/BW)降低以及肥大标志物心房钠尿肽(ANF)、脑钠肽(BNP)和β-肌球蛋白重链(β-MHC)表达减少;它还预防了Ang II诱导的心脏纤维化,这表现为细胞外基质(ECM)成分I型胶原、III型胶原和纤连蛋白(FN)过量积累减少。进一步的研究表明,6014处理不影响PARP-1的表达水平,但剂量依赖性地抑制PARP-1的活性,随后由于NAD+消耗减少和SIRT-1的聚ADP核糖基化(PARylation)减弱而恢复了心脏组织中SIRT-1的活性状态。总之,新型PARP-1抑制剂6014能有效保护小鼠免受Ang II诱导的心脏重塑并改善心脏功能。因此,6014可能是一种潜在的心脏病治疗药物。

相似文献

2
AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Mol Cell Endocrinol. 2014 Jul 5;392(1-2):14-22. doi: 10.1016/j.mce.2014.05.010. Epub 2014 May 21.
4
Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways.
Acta Pharmacol Sin. 2014 Apr;35(4):463-75. doi: 10.1038/aps.2013.185. Epub 2014 Mar 10.
5
Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.
Amino Acids. 2021 Oct;53(10):1533-1543. doi: 10.1007/s00726-021-03074-9. Epub 2021 Sep 7.
6
SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.
Circulation. 2017 Nov 21;136(21):2051-2067. doi: 10.1161/CIRCULATIONAHA.117.028728. Epub 2017 Sep 25.
7
Salvianolic acid B protects cardiomyocytes from angiotensin II-induced hypertrophy via inhibition of PARP-1.
Biochem Biophys Res Commun. 2014 Feb 14;444(3):346-53. doi: 10.1016/j.bbrc.2014.01.045. Epub 2014 Jan 22.
8
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy.
Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1545-53. doi: 10.1152/ajpheart.01124.2005. Epub 2006 Apr 21.
9
Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
Cardiovasc Drugs Ther. 2017 Apr;31(2):157-166. doi: 10.1007/s10557-017-6719-0.

引用本文的文献

1
Quercetin Attenuates Cardiac Hypertrophy by Inhibiting Mitochondrial Dysfunction Through SIRT3/PARP-1 Pathway.
Front Pharmacol. 2021 Oct 28;12:739615. doi: 10.3389/fphar.2021.739615. eCollection 2021.
2
The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy.
Acta Pharm Sin B. 2021 May;11(5):1286-1299. doi: 10.1016/j.apsb.2020.12.012. Epub 2020 Dec 14.
3
SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity.
Aging (Albany NY). 2020 Mar 4;12(5):4178-4192. doi: 10.18632/aging.102862.
4
Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation.
Acta Pharm Sin B. 2019 Jul;9(4):782-793. doi: 10.1016/j.apsb.2018.10.008. Epub 2018 Nov 1.
5
Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond.
Br J Pharmacol. 2019 Nov;176(22):4319-4339. doi: 10.1111/bph.14363. Epub 2018 Jun 25.
6
SIRT1 and SIRT6 Signaling Pathways in Cardiovascular Disease Protection.
Antioxid Redox Signal. 2018 Mar 10;28(8):711-732. doi: 10.1089/ars.2017.7178. Epub 2017 Jun 29.

本文引用的文献

1
Role of Sirtuins in Regulating Pathophysiology of the Heart.
Trends Endocrinol Metab. 2016 Aug;27(8):563-573. doi: 10.1016/j.tem.2016.04.015. Epub 2016 May 19.
2
SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy.
Int J Cardiol. 2016 Feb 15;205:99-110. doi: 10.1016/j.ijcard.2015.12.008. Epub 2015 Dec 15.
3
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside.
Eur Heart J. 2015 Dec 21;36(48):3404-12. doi: 10.1093/eurheartj/ehv290. Epub 2015 Jun 25.
4
AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Mol Cell Endocrinol. 2014 Jul 5;392(1-2):14-22. doi: 10.1016/j.mce.2014.05.010. Epub 2014 May 21.
5
Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis.
Hepatology. 2014 May;59(5):1998-2009. doi: 10.1002/hep.26763. Epub 2014 Apr 1.
6
Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications.
Med Res Rev. 2014 May;34(3):644-75. doi: 10.1002/med.21300. Epub 2013 Sep 3.
7
Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1.
Am J Pathol. 2013 Jan;182(1):71-83. doi: 10.1016/j.ajpath.2012.09.004.
8
Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats.
Int J Cardiol. 2013 Sep 1;167(5):2285-93. doi: 10.1016/j.ijcard.2012.06.050. Epub 2012 Jul 28.
9
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.
Genes Dev. 2012 Mar 1;26(5):417-32. doi: 10.1101/gad.183509.111.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验